Jazz Veno-Occlusive Disease Drug Defitelio OK'd

Jazz Pharmaceuticals PLC won the FDA's approval on March 30 for the company's anticoagulant Defitelio (defibrotide) as a treatment for adults and children with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) – the first medicine available in the US for that indication.